DE50304970D1 - Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie - Google Patents

Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie

Info

Publication number
DE50304970D1
DE50304970D1 DE50304970T DE50304970T DE50304970D1 DE 50304970 D1 DE50304970 D1 DE 50304970D1 DE 50304970 T DE50304970 T DE 50304970T DE 50304970 T DE50304970 T DE 50304970T DE 50304970 D1 DE50304970 D1 DE 50304970D1
Authority
DE
Germany
Prior art keywords
feminine
increased
receptor modulators
progesterone receptor
hormone response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE50304970T
Other languages
German (de)
English (en)
Inventor
Alexander Hillisch
Walter Elger
Gerd Schubert
Birgitt Schneider
Gudrun Reddersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10236405A external-priority patent/DE10236405A1/de
Application filed by Schering AG filed Critical Schering AG
Priority to DE50304970T priority Critical patent/DE50304970D1/de
Application granted granted Critical
Publication of DE50304970D1 publication Critical patent/DE50304970D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE50304970T 2002-08-02 2003-08-01 Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie Expired - Lifetime DE50304970D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE50304970T DE50304970D1 (de) 2002-08-02 2003-08-01 Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40006502P 2002-08-02 2002-08-02
DE10236405A DE10236405A1 (de) 2002-08-02 2002-08-02 Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
PCT/EP2003/008572 WO2004014935A1 (de) 2002-08-02 2003-08-01 Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE50304970T DE50304970D1 (de) 2002-08-02 2003-08-01 Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie

Publications (1)

Publication Number Publication Date
DE50304970D1 true DE50304970D1 (de) 2006-10-19

Family

ID=31716602

Family Applications (1)

Application Number Title Priority Date Filing Date
DE50304970T Expired - Lifetime DE50304970D1 (de) 2002-08-02 2003-08-01 Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie

Country Status (8)

Country Link
EP (1) EP1525215B1 (OSRAM)
JP (1) JP2005539016A (OSRAM)
AT (1) ATE338763T1 (OSRAM)
AU (1) AU2003255355A1 (OSRAM)
DE (1) DE50304970D1 (OSRAM)
DK (1) DK1525215T3 (OSRAM)
ES (1) ES2273061T3 (OSRAM)
WO (1) WO2004014935A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011762A1 (it) 2001-08-10 2003-02-10 Cosmo Spa Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
DE102006018869A1 (de) * 2006-04-13 2007-10-18 Bayer Schering Pharma Ag 17alpha-substituierte 4-(3-Oxoestra-4,9-dien-11beta-yl)-benzoesäure, deren Derivate und Verfahren zu ihrer Herstellung
EP1924556A2 (en) * 2006-06-28 2008-05-28 Teva Pharmaceutical Industries Ltd Crystalline forms of atorvastatin
WO2008109719A2 (en) * 2007-03-07 2008-09-12 Janssen Pharmaceutica N.V. Steroids derivatives as selective progesterone receptor modulators
ITMI20071616A1 (it) 2007-08-03 2009-02-04 Cosmo Spa Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
EP2348318A1 (en) * 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
JP6920062B2 (ja) 2014-06-17 2021-08-18 アイジェノミクス エセ．エレ． 子宮内膜病変における幹細胞治療
EP3108879A1 (en) 2015-06-25 2016-12-28 Cassiopea S.p.A. High concentration formulation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504421A1 (de) * 1985-02-07 1986-08-07 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 11ss-phenyl-gonane, deren herstellung und diese enthaltende pharmazeutische praeparate
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332284C2 (de) * 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19745085A1 (de) * 1997-10-11 1999-04-15 Jenapharm Gmbh 11ß-Benzaldoxim-9alpha,10alpha-epoxy-estr-4-en-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
AR025457A1 (es) * 1999-08-31 2002-11-27 Schering Ag Mesoprogestinas (moduladores de receptores de progesterona) para el tratamiento y la prevencion de trastornos ginecologicos benignos hormona-dependientes
EA006805B1 (ru) * 1999-08-31 2006-04-28 Шеринг Акциенгезельшафт Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента женских контрацептивов
UA75339C2 (en) * 1999-08-31 2006-04-17 Schering Ag Use of mesoprogestins (progesterone receptor modulators) as pharmaceutical components for manufacture of medicament for hormone replacement therapy (hrt)
DE19961219A1 (de) * 1999-12-15 2001-07-19 Jenapharm Gmbh 11beta-Phenylestratrien-Derivate mit Fluoralkylgruppen in der aromatischen Seitenkette, deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
EP1525215A1 (de) 2005-04-27
WO2004014935A1 (de) 2004-02-19
JP2005539016A (ja) 2005-12-22
DK1525215T3 (da) 2007-01-15
EP1525215B1 (de) 2006-09-06
ATE338763T1 (de) 2006-09-15
ES2273061T3 (es) 2007-05-01
AU2003255355A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
ATE338763T1 (de) Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
MX2007004862A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias.
GB0222495D0 (en) Compounds
DE60220887D1 (de) Agonisten von beta-adrenorezeptoren
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
MY137053A (en) Pyrimidine derivatives and their use as cb2 modulators
BRPI0409136A (pt) composto heteroaromático pentacìclico e uso medicinal do mesmo
NO20061736L (no) Krystallform av epotilon B
SE9904505D0 (sv) Novel compounds
NO20003414D0 (no) Anvendelse av PPAR-<ypsilon> aktivatorer i dermatologi
NO964155D0 (no) Progesteronantagonister for fremstilling av legemidler til behandling av dysfunksjonelle uterusblödninger
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
GEP20074244B (en) Compounds that modulate ppar activity and methods for their preparation
MY137535A (en) New pyrrolidinium derivatives
DK1060163T3 (da) Nye piperazinyl-substituerede pyridylalkan-, -alken og -alkyncarboxamider
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BRPI0512974A (pt) novos derivados de hidantoìna para o tratamento de doenças obstrutivas das vias aéreas
AU2000233235A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
PT1506185E (pt) Compostos novos e sua utilizacao
ATE218142T1 (de) Nitratester von corticoid verbindungen und die therapeutische verwendungen davon
BR9307746A (pt) Derivados de esteróides especificos para otratamento de cólon e ileo
BR0012610A (pt) Novo derivado de difenilpiperidina
SE0103819D0 (sv) Chemical compounds
DE60221537D1 (de) Pteridinon-derivate als modulatoren der chemokinrezeptor-aktivität

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AG, 13353 BERLIN, DE

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKIENGESELLSCHAFT, 13353, DE